Strategy Consulting

Stephan Gauldie, PhD
Senior Vice President

Dr. Stephan Gauldie joined Back Bay at its founding in 2010 and has been active in building the firm’s offering across company size and sector.  His role places particular emphasis on Strategic Franchise Building, M&A and Licensing Strategy, Buy Side Diligence, and Liquidity Planning and Positioning for Emerging Growth Companies.  In addition to his senior consulting role, Stephan is a member of Back Bay’s Financial Advisory team, providing market and scientific analytics in Sell Side and Buy Side engagements.

Stephan has over 15 years of experience across drug development research, market analysis, and strategy consulting.  Prior to joining Back Bay, he led the Commercial Research Group at Decision Resources and was a Principal Analyst at Wood Mackenzie, leading teams that covered US and EU-based pharmaceutical companies, as well as CNS/Pain and Immunology therapeutic areas.

Stephan obtained his doctorate in Neuropharmacology from the University of Edinburgh Medical School, in collaboration with GlaxoSmithKline’s Neurology and Gastrointestinal Center for Early Drug Discovery (CEDD), and completed a post-doctoral fellowship in the Department of Pharmacology at the same institution.

Stephan also holds undergraduate degrees in Medicinal Chemistry and Psychology from Queen’s University, Canada.

Recent Posts by Stephan

Navigating transaction value at the early stage – a process for internal and external preclinical transaction analyses

Determining preclinical-stage candidate value can be challenging, but when the principal developer is also an early-stage “platform company” (ESPC), with ... Read More

Stephan Gauldie Interviewed by PharmaVOICE on drug-device combination development

Dr. Stephan Gauldie was recently interviewed by PharmaVOICE on drug-device combination development, where he discussed some of the challenges that ... Read More

BioPharma Puts Skin in Atopic Dermatitis Game: Strategy/Transaction Insights

By: Stephan Gauldie, PhD and S. Peter Bak, PhD Atopic dermatitis – set to outpace psoriasis as the largest dermatology market? Atopic dermatitis ... Read More